Paid Clinical Trials Michigan
Discover 2,118 paid clinical trials in Michigan. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
A Study of EP0031 in Patients With Advanced RET-altered MalignanciesA Study of EP0031 in Patients With Advanced RET-altered Malignancies
Sponsor:
Ellipses Pharma
Location:
Code:
NCT05443126
Conditions
Advanced Solid Tumor
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
EP0031
A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer.A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer.
Sponsor:
University College, London
Location:
Code:
NCT01792726
Conditions
Early Breast Cancer
Eligibility Criteria
Sex: Female
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
Boost to the tumour bed
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative ColitisA Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
Sponsor:
Pfizer
Location:
Code:
NCT05287126
Conditions
Ulcerative Colitis
Eligibility Criteria
Sex: All
Age: 12 - 17
Healthy Volunteers: Not accepted
Interventions
Etrasimod
A Trial Comparing Unrelated Donor BMT with IST for Pediatric and Young Adult Patients with Severe Aplastic Anemia (TransIT, BMT CTN 2202)A Trial Comparing Unrelated Donor BMT with IST for Pediatric and Young Adult Patients with Severe Aplastic Anemia (TransIT, BMT CTN 2202)
Sponsor:
Boston Children's Hospital
Location:
Code:
NCT05600426
Conditions
Severe Aplastic Anemia
Eligibility Criteria
Sex: All
Age: 0 - 25
Healthy Volunteers: Not accepted
Interventions
cyclosporine
Matched Unrelated Donor Hematopoetic Stem Cell Transplant
horse anti-thymocyte globulin (ATG)
rabbit anti-thymocyte globulin (ATG)
Methotrexate
Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast CancerPhase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Sponsor:
Ellipses Pharma
Location:
Code:
NCT05573126
Conditions
Hormone Receptor-positive Breast Cancer
Hormone Receptor Positive HER-2 Negative Breast Cancer
Metastatic Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Vosilasarm
Elacestrant
Everolimus
Stimulation to Improve MemoryStimulation to Improve Memory
Sponsor:
University of Michigan
Location:
Code:
NCT03875326
Conditions
Mild Cognitive Impairment
Dementia of Alzheimer Type
Eligibility Criteria
Sex: All
Age: 55+
Healthy Volunteers: Not accepted
Interventions
1 mA HD-tDCS
2 mA HD-tDCS
3 mA HD-tDCS
Sham
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Breast CancerPharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Breast Cancer
Sponsor:
University of Michigan Rogel Cancer Center
Location:
Code:
NCT05183126
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Paclitaxel
TH1902 in Patients With Advanced Solid TumorsTH1902 in Patients With Advanced Solid Tumors
Sponsor:
Theratechnologies
Location:
Code:
NCT04706962
Conditions
Solid Tumor
TNBC - Triple-Negative Breast Cancer
Hormone Receptor-positive Breast Cancer
Epithelial Ovarian Cancer
Endometrial Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
TH1902
A Study of SGN-PDL1V in Advanced Solid TumorsA Study of SGN-PDL1V in Advanced Solid Tumors
Sponsor:
Seagen Inc.
Location:
Code:
NCT05208762
Conditions
Carcinoma, Non-Small-Cell Lung
Squamous Cell Carcinoma of the Head and Neck
Esophageal Squamous Cell Carcinoma
Ovarian Neoplasms
Melanoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
PF-08046054
pembrolizumab
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
Sponsor:
Chimerix
Location:
Code:
NCT05580562
Conditions
H3 K27M
Glioma
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
Dordaviprone (ONC201)
Dordaviprone (ONC201) + Placebo
Placebo